Applied NeuroSolutions, Inc.
50 Lakeview Parkway
Suite 111
Vernon Hills
Illinois
60061
United States
Tel: 847-573-8025
Fax: 847-573-8030
Website: http://www.appliedneurosolutions.com/
Email: ellison@appns.com
38 articles about Applied NeuroSolutions, Inc.
-
Applied NeuroSolutions, Inc. to Present at OneMedPlace Finance Forum for Emerging Healthcare and Life Science Companies
1/5/2010
-
Applied NeuroSolutions, Inc. Announces Increased Scope of Alzheimer's Disease Drug Discovery Collaboration With Eli Lilly and Company (JOBS); Applied NeuroSolutions Will Receive Up-front Cash Payment of $750,000 and May Receive up to $25.5 Million in Mile
12/22/2009
-
Applied NeuroSolutions, Inc. Announces Renewal of Alzheimer's Disease Drug Discovery Collaboration with Eli Lilly and Company
12/8/2009
-
Applied NeuroSolutions, Inc. Updates Promising Results for a Blood-Based Test for Alzheimer's Disease
10/9/2009
-
Applied NeuroSolutions, Inc. Appoints Craig Taylor as President & CEO
9/1/2009
-
Applied NeuroSolutions, Inc. Announces Promising Results for a Blood-Based Test for Alzheimer's Disease
7/23/2009
-
Applied NeuroSolutions, Inc.’s Renews Agreement with Noted Alzheimer’s Disease Researcher, Peter Davies, Ph.D.
12/22/2008
-
Applied NeuroSolutions, Inc.’s Q3 2008 Alzheimer’s Disease Serum Diagnostic Development Program Update
11/19/2008
-
Applied NeuroSolutions, Inc. Announces Addition of Healthcare Financial Executive Gary C. Parks to Board of Directors
11/17/2008
-
Applied NeuroSolutions, Inc. Announces Addition of Diagnostic Healthcare Executive Edward Ogunro, Ph.D., to Board of Directors
11/3/2008
-
Applied NeuroSolutions, Inc. Engages William Blair & Company, LLC as its' Strategic Advisor
9/8/2008
-
Applied NeuroSolutions, Inc.' Founding Scientist, Peter Davies, Ph.D., to Receive Lifetime Achievement Award from Alzheimer's Association
7/28/2008
-
Applied NeuroSolutions, Inc. Achieves Q2 2008 Alzheimer’s Disease Serum Diagnostic Development Program Milestone
7/1/2008
-
Applied NeuroSolutions, Inc. Q1 2008 Alzheimer's Disease Diagnostic Development Programs Update
5/20/2008
-
Applied NeuroSolutions, Inc. to Offer P-Tau 231 Test for Use in Alzheimer's Disease Clinical Trials
5/13/2008
-
Study Shows Applied NeuroSolutions, Inc.' s Test is a Significant Predictor of the Decline from Mild Cognitive Impairment to Alzheimer's Disease
12/18/2007
-
Applied NeuroSolutions, Inc.'s Founding Scientist, Dr. Peter Davies, to Participate on an Expert Panel on Alzheimer's Disease Hosted by Credit Suisse
12/13/2007
-
Applied NeuroSolutions, Inc. Appoints Ellen R. Hoffing to Additional Role as Chairman of the Board of Directors
12/13/2007
-
Applied NeuroSolutions, Inc. Appoints Healthcare Executive David C. Tiemeier, Ph.D. to Board of Directors
10/25/2007
-
Study Shows Applied NeuroSolutions, Inc.'s Test is the Strongest Predictor of the Decline from Mild Cognitive Impairment to Alzheimer's Disease
10/15/2007